B
테라젠이텍스
066700KOSDAQ57.0 / 100
Reference Date: 2026-10-23
Financial Score29.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Declined 8.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Teragen I-teks operates primarily in pharmaceutical manufacturing and sales, as well as genomic sequencing services. Its subsidiaries, Lead Pharm and Teragen Healthcare, specialize in specialty drug distribution and non-drug medical product sales, respectively. Additionally, Teragen Bio and overseas subsidiaries are expanding genomic analysis services into the Chinese market.
Number of Employees
222people
Average Salary
50.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
6.82Industry Average 15.008.0Point
Half of industry avg (excellent)
PBR
0.47Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
8.11Industry Average 8.004.0Point
In line with industry avg
Debt Ratio
5.84Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲10.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼5.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -0.4% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (9%, downtrend)
Current 2,020Won52-week high 3,31552-week low 1,888
1-month return1.0Point
1m -8.60% (falling)
Volume trend3.0Point
Volume flat
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-19
- Neutral전환가액의조정2026-10-19
- Neutral주식소각결정2026-09-29